However, PHD2 expression levels remained consistent across CRC cells treated with either CAFS-CM or CAFR-CM, regardless of WARS2-IT1 status, suggesting minimal effect on PHD2 expression or stability (Fig. 4E). This evidence concerns the gene EGLN1 and colorectal carcinoma.